摘要
目的研究分析非小细胞肺癌(NSCLC)患者中ALK、ROS1及BRAF-V600E基因的突变状态,分析其突变率与患者的年龄、性别、吸烟史、组织学分型等临床病理特征的关系,为精准治疗提供依据。方法采用PCR方法检测1 042例NSCLC患者ALK、ROS1及114例NSCLC患者BRAF-V600E基因突变情况,并分析基因突变与患者临床病理特征的关系。结果在1 042例NSCLC患者中,ALK和ROS1基因融合突变阳性率分别为3.84%和1.54%,其中女性患者阳性率分别为3.86%和0.61%,男性为3.82%和2.36%;年龄≥60岁的患者为3.04%和0.71%,<60岁的患者为4.77%和2.49%;吸烟者阳性率分别为4.10%和1.28%,不吸烟患者为3.68%和1.69%。114例肺腺癌患者中BRAF-V600E基因突变率为5.26%,男性5.97%,女性4.26%;年龄≥60岁4.44%,年龄<60岁5.80%;吸烟与无吸烟史的阳性率分别为3.92%和6.35%。结论年龄是ALK、ROS1基因融合突变的显著相关因素,而ROS1基因突变更常见于男性患者。推荐在NSCLC患者中进行多基因联合检测,为指导临床靶向治疗提供依据。
Objective To investigate the mutation status of ALK,ROS1 and BRAF-V600E genes in NSCLC patients,and to analyze the relationship between the mutation status and the clinicopathological characteristics of NSCLC patients.Methods PCR was used to detect ALK,ROS1 in 1042 NSCLC patients and BRAF-V600E gene mutation in 114 NSCLC patients,and to analyze the relationship between the gene mutation and the clinicopathological characteristics of the patients.Results Among 1,042 NSCLC patients,the ALK and ROS1 gene fusion mutation positive rates were 3.84%and 1.54%,of which female patients were 3.86%and 0.61%,and males were 3.82%and 2.36%.3.04%and 0.71%of patients were≥60 years old,and 4.77%and 2.49%of patients<60 years old.The positive rates of smokers were 4.10%and 1.28%,respectively,and non-smokers were 3.68%and 1.69%.In 114 lung adenocarcinoma patients,the mutation rate of BRAF-V600E gene was 5.26%,male 5.97%,female 4.26%.Age≥60 years old 4.44%,age<60 years old 5.80%.The positive rates of smoking and no smoking history were 3.92%and 6.35%respectively.There was significant difference in ALK and ROS1 gene mutation rates among NSCLC patients of different age.Conclusion Age is a significant related factor for ALK and ROS1 gene fusion mutations,and ROS1 gene mutations are more common in male patients.It is recommended to carry out multi-gene joint detection in NSCLC patients to provide a basis for guiding clinical targeted therapy.
作者
李华芳
LI Huafang(Department of Pathology,The second people hospital of Dezhou,Dezhou,Shangdong,China,253000)
出处
《分子诊断与治疗杂志》
2020年第6期701-704,719,共5页
Journal of Molecular Diagnostics and Therapy
